Galleon Pharmaceuticals
Neuro-respiratory medicines for treating breathing control conditions
About Galleon Pharmaceuticals
Galleon Pharmaceuticals, Inc. was a pharmaceutical company focused on developing medical drugs to treat conditions related to breathing control. The company was founded in 2003 and was headquartered in Horsham, Pennsylvania. Pitchbook lists James Mannion as the founder and former CEO, who was later succeeded by Joseph Oliveto.
The company's main focus was on creating neuro-respiratory medicines for a range of diseases including sleep apnea, weaning from ventilators, respiratory depression induced by anesthesia, and obesity-hypoventilation syndrome. Their product pipeline included GAL-021, an intravenous drug designed to treat or prevent acute respiratory insufficiency in surgical and critical-care patients. This drug showed positive results in a Phase I clinical study by increasing the capacity of air supplied to the lungs. Galleon also had two other products in preclinical development, GAL-160 oral and GAL-160 oral backups, both intended for sleep apnea treatment.
Galleon Pharmaceuticals was a privately held, venture capital-backed company. It raised approximately $69.6 million in funding from investors, including Ben Franklin Technology Partners of Southeastern Pennsylvania, TPG Biotech, Morgenthaler Ventures, and Healthcare Ventures. In May 2006, the company was named the SR One Biotech Company of the Year. According to PitchBook, the company is now out of business as of February 2019.
Source: Dealroom company dataNews
Open roles
Galleon Pharmaceuticals in the Horsham Township ecosystem
The Galleon Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
BioAdvance
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Galleon Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Galleon Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

